- Home
- ARGX vs ANSS Comparison
ARGX vs ANSS Comparison
Compare ARGX & ANSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ANSS
- Stock Information
- Founded
- ARGX 2008
- ANSS 1970
- Country
- ARGX Netherlands
- ANSS United States
- Employees
- ARGX N/A
- ANSS N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ANSS Computer Software: Prepackaged Software
- Sector
- ARGX Health Care
- ANSS Technology
- Exchange
- ARGX Nasdaq
- ANSS Nasdaq
- Market Cap
- ARGX 35.3B
- ANSS 30.4B
- IPO Year
- ARGX 2017
- ANSS 1996
- Fundamental
- Price
- ARGX $573.26
- ANSS $330.82
- Analyst Decision
- ARGX Strong Buy
- ANSS Hold
- Analyst Count
- ARGX 20
- ANSS 3
- Target Price
- ARGX $698.22
- ANSS $352.50
- AVG Volume (30 Days)
- ARGX 493.8K
- ANSS 819.4K
- Earning Date
- ARGX 05-08-2025
- ANSS 04-30-2025
- Dividend Yield
- ARGX N/A
- ANSS N/A
- EPS Growth
- ARGX N/A
- ANSS 35.35
- EPS
- ARGX 15.94
- ANSS 6.74
- Revenue
- ARGX $2,643,062,000.00
- ANSS $2,583,095,000.00
- Revenue This Year
- ARGX $61.64
- ANSS $11.68
- Revenue Next Year
- ARGX $32.00
- ANSS $9.99
- P/E Ratio
- ARGX $32.97
- ANSS $49.12
- Revenue Growth
- ARGX 82.13
- ANSS 15.98
- 52 Week Low
- ARGX $359.37
- ANSS $275.06
- 52 Week High
- ARGX $678.21
- ANSS $363.03
- Technical
- Relative Strength Index (RSI)
- ARGX 45.96
- ANSS 48.37
- Support Level
- ARGX $570.00
- ANSS $321.60
- Resistance Level
- ARGX $584.90
- ANSS $349.07
- Average True Range (ATR)
- ARGX 14.55
- ANSS 7.32
- MACD
- ARGX 0.82
- ANSS -2.32
- Stochastic Oscillator
- ARGX 66.03
- ANSS 31.68
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About ANSS ANSYS Inc.
Ansys is an engineering software company that provides simulation capabilities for structural, fluids, semiconductor power, embedded software, optical, and electromagnetic properties. Ansys employs over 4,000 people and serves over 50,000 customers globally.